# 5 Quanterix | SR-X Ultra-Sensitive Biomarker Detection System
In The News
SelectScience | November 30, 2017
Kevin Hrusovsky is President and CEO of Quanterix, a company that is developing an ultrasensitive immunoassay platform that is capable of detecting very low levels of biomarkers in the body. Watch this exclusive interview to discover Hrusovsky’s vision for the future of healthcare.
Alzforum | November 17, 2017
Serum NfL levels rise before symptoms appear in familial AD. NfL correlates with cognitive decline and brain atrophy. In MS patients, NfL levels drop with treatment.
The Guardian| October 30, 2017
Several firms trying to develop new methods to assess extent of damage
GEN| October 27, 2017
Companion Diagnostic Development Gets More Complex for Immune Therapies and Other Indications Outside Oncology
Genetic Engineering & Biotechnology News | October 16, 2017
Improve Detection Limits and Preserve Sample Volumes with High-Sensitivity Multiplexing Assays
CLP Magazine | September 26, 2017
Quanterix Corp, Lexington, Mass, is expanding its single molecule array, or Simoa, portfolio to include the new Quanterix SR-Plex benchtop instrument.
Alzforum | September 21, 2017
In this month’s JAMA Neurology, two papers examine whether tau circulating in plasma could offer a blood-based biomarker for brain disorders.
Biocompare | September 19, 2017
Tracking multiple targets in one reaction is an increasing requirement of assays being used in molecular biology and medicine.